The treatment — which could be the first novel antimalarial in decades — showed the ability in testing to combat drug ...

The “plausible mechanism” pathway, outlined by Martin Makary and Vinay Prasad, is designed to help accelerate treatments ...

Metagenomi is laying of 25% of its staff while switching up leadership. Elsewhere, Ovid announced a CEO succession plan and ...

The appointment of Pazdur as CDER head comes shortly after the surprise ousting of George Tidmarsh and should quiet many of ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Skyrocketing healthcare costs could deliver another blow to the industry’s ongoing quest to boost representation in R&D.

The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a ...

Merck’s pill, which could be the first oral PCSK9 drug to get to market, displayed similar effects on lipid levels as ...

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...